Compare KFRC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | DRTS |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.3M | 607.1M |
| IPO Year | 1995 | N/A |
| Metric | KFRC | DRTS |
|---|---|---|
| Price | $36.94 | $6.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $36.25 | $8.00 |
| AVG Volume (30 Days) | 183.7K | ★ 505.8K |
| Earning Date | 02-02-2026 | 03-11-2026 |
| Dividend Yield | ★ 4.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,329,007,000.00 | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | $18.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.49 | $2.30 |
| 52 Week High | $55.40 | $7.89 |
| Indicator | KFRC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 58.19 |
| Support Level | $32.39 | $6.75 |
| Resistance Level | $35.95 | $7.78 |
| Average True Range (ATR) | 1.51 | 0.61 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 76.44 | 52.40 |
Kforce Inc is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. The company operates two business segments: 1) In technology segment it provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. 2) In FA segment company offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting business and cost analysis; and taxation and treasury. The majority of revenue is earned through the technology segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.